AVENTURA, Fla. and NATICK,
Mass., May 18, 2022 /PRNewswire/ -- Cytovia
Therapeutics, LLC ("Cytovia Therapeutics"), a global
biotechnology company focused on harnessing the power of natural
killer (NK) cells to fight cancer through multispecific antibodies
and stem cell engineering, announced today that it will be
presenting at the the Annual European Hematology Association's
(EHA) 2022 Hybrid Congress, taking place June 9 – 12, 2022 at the Messe Wien Exhibition
and Congress Center in Vienna,
Austria, and online.
The abstract was released on May 12, 2022. The e-poster presentation will be
published on the virtual congress platform on Friday, June 10.
Details of Cytovia's poster
presentation:
Title: NOVEL MULTIFUNCTIONAL TETRAVALENT
CD38 NKP46 FLEX-NK ENGAGERS ACTIVELY TARGET AND KILL MULTIPLE
MYELOMA CELLS
Session Title: Poster session
Session date and time: Friday, June 10, 2022 - 16:30 - 17:45 CEST
Final Abstract Code: P842
Presenting Author: Jean Christophe
Bories
Summary: CYT-338 is a tetravalent IgG1-like multifunctional NK cell
engager antibody with a novel FLEX-linker that simultaneously binds
CD38-expressing cells and NK cells via the activation receptor
NKp46. The in vitro and in vivo activity of
CYT-338 was studied in myeloma models. CYT-338 showed specific
dose-dependent binding to CD38 expressing MM cells with ~ 2-fold
higher mean fluorescence intensity than daratumumab. Epitope
mapping studies suggest binding of CYT-338 to a CD38 epitope
distinct from daratumumab. CYT-338 showed greater dose dependent NK
cell redirected cytolysis, degranulation, and cytokine production
against MM1S cells compared to daratumumab. CYT-338 combined with
peripheral blood NK cells inhibited tumor growth in a MM1S-NSG
mouse model. CYT-338 showed minimal immune subset depletion, NK
cell fratricide, and cytokine release compared to daratumumab in
human PBMCs in-vitro. These results suggest that the CYT-338
engager has a favorable NK cell engager profile for targeting
CD38-expressing multiple myeloma distinct from daratumumab.
About Cytovia Therapeutics
Cytovia Therapeutics is developing novel cell therapies and
immunotherapies aimed at addressing solid and hematological tumors
with significant unmet medical needs. Cytovia Therapeutics is
focusing on harnessing the innate immune system by developing
complementary and disruptive NK-cell and NK-engager antibody
platforms. The company is developing three types of iPSC-derived
(or iNK) cells: unedited iNK cells, TALEN® gene-edited iNK cells
with improved function and persistence, and TALEN® gene-edited iNK
cells with chimeric antigen receptors (CAR-iNKs) to improve
tumor-specific targeting. The second complementary cornerstone
technology is a quadrivalent multifunctional antibody platform
designed to engage natural killer cells by targeting NKp46 using
Cytovia Therapeutics's proprietary Flex-NK™ technology.
These two technology platforms are being used to develop
treatments for patients with solid tumors such as HCC and
glioblastoma as well as hematological malignancies such as
refractory multiple myeloma.
Headquartered in Aventura, FL, Cytovia Therapeutics has
research and development laboratories in Natick, MA, and a
cell manufacturing facility in Puerto Rico. The company's own
R&D work is augmented through scientific partnerships with
Cellectis, CytoImmune, the Hebrew University
of Jerusalem, INSERM, the New York Stem Cell Foundation and
the University of California San Francisco (UCSF).
Cytovia Therapeutics has a strategic partnership with CytoLynx
Therapeutics, which is focused on research and development,
manufacturing, and commercialization activities in Greater
China and beyond.
As previously announced on April 26,
2022, Cytovia Therapeutics entered into a Merger Agreement
and Plan of Reorganization with Isleworth Healthcare Acquisition
Corp. ("Isleworth"), a publicly traded special purpose acquisition
company, providing for a business combination that would result in
Cytovia Therapeutics becoming a publicly traded company. The
transaction is expected to close in the second half of 2022,
subject to the satisfaction of customary closing conditions,
including the approval of the shareholders of Cytovia Therapeutics
and Isleworth.
Find out more at www.cytoviatx.com and follow us
on Facebook, Twitter, LinkedIn, YouTube,
and Instagram.
About CD38
Cluster of differentiation 38 (CD38) is a
type II receptor membrane glycoprotein that plays a role in cell
adhesion, migration, and signal transduction.
Additionally, CD38 is an ectoenzyme involved in
generation of nucleotide metabolites, such as ADP-Ribose
that regulate cell metabolism. CD38 is highly expressed in
multiple myeloma (MM) on malignant plasma cells and is also
moderately expressed on normal T, B, NK and myeloid cells.
Antibodies targeting CD38, such as daratumumab and isatuximab, are
FDA approved for the treatment of MM as monotherapy and in
combination.
Additional Information and Where to Find It
Isleworth
Healthcare Acquisition Corp. ("Isleworth")
(NASDAQ: ISLE) intends to file a registration statement
on Form S-4 with the Securities Exchange Commission (the "SEC"),
which will include a proxy statement/prospectus, that will be both
the proxy statement to be distributed to holders of Isleworth's
common stock in connection with its solicitation of proxies for the
vote by Isleworth's stockholders with respect to the proposed
business combination pursuant to an Merger Agreement and Plan of
Reorganization entered into on April 26, 2022, by and between
Isleworth, Cytovia Holdings, Inc., the parent company of
Cytovia Therapeutics ("Cytovia"), IHAC First Merger Sub Inc., a
direct, wholly-owned subsidiary of Isleworth, IHAC Second Merger
Sub LLC, direct, wholly-owned subsidiary of Isleworth, and
Isleworth Healthcare Sponsor I, LLC (the "Business Combination")
and other matters as may be described in the registration
statement, as well as the prospectus relating to the offer and sale
of the securities to be issued in the business combination. After
the registration statement is declared effective, Isleworth will
mail a definitive proxy statement/prospectus and other relevant
documents to its stockholders. This communication does not contain
all the information that should be considered concerning the
Business Combination and is not intended to form the basis of any
investment decision or any other decision in respect of the
business combination. Isleworth's stockholders and other interested
persons are advised to read, when available, the preliminary proxy
statement/prospectus included in the registration statement and the
amendments thereto and the definitive proxy statement/prospectus
and other documents filed in connection with the Business
Combination, as these materials will contain important information
about Cytovia, Cytovia Therapeutics, Isleworth and the Business
Combination. When available, the definitive proxy
statement/prospectus and other relevant materials for the Business
Combination will be mailed to stockholders of Isleworth as of a
record date to be established for voting on the Business
Combination. Stockholders will also be able to obtain copies of the
preliminary proxy statement, the definitive proxy statement and
other documents filed with the SEC, without charge, once available,
at the SEC's website at www.sec.gov, or by directing a request
to Isleworth's secretary at 360 Central Avenue, First Central
Tower, Suite #800, St. Petersburg, Florida 33701.
Participants in the Solicitation
Isleworth, Cytovia
and their respective directors, executive officers and other
members of their management and employees, under SEC rules, may be
deemed to be participants in the solicitation of proxies from
Isleworth stockholders in connection with the proposed transaction.
Investors and security holders may obtain more detailed information
regarding the names, affiliations and interests of Isleworth
directors and executive officers in Isleworth's Annual Report on
Form 10-K for the fiscal year ended December 31, 2021, which
was filed with the SEC on March 29, 2022. To the extent that
holdings of Isleworth securities have changed since the filing of
the Annual Report on Form 10-K, such changes have been or will be
reflected on Statements of Change in Ownership on Form 4 filed with
the SEC. Information regarding the persons who may, under SEC
rules, be deemed participants in the solicitation of proxies of
Isleworth stockholders in connection with the proposed transaction
will be set forth in the proxy statement/information
statement/prospectus for the proposed transaction when available.
Information concerning the interests of Isleworth participants in
the solicitation, which may, in some cases, be different than those
of Isleworth Healthcare Acquisition Corp.'s equity holders
generally, will be set forth in the proxy statement/information
statement/prospectus relating to the proposed transaction when it
becomes available.
Forward Looking Statements
This press release may
contain forward-looking statements, which may be identified by
words such as "aims," "anticipates," "believes," "could,"
"estimates," "expects," "forecasts," "goal," "intends," "may,"
"plans," "possible," "potential," "seeks," "will" and variations of
these words or similar expressions that are intended to identify
forward-looking statements, although not all forward-looking
statements contain these words. Forward-looking statements in this
press release include, but are not limited to, statements regarding
the potential of Cytovia's FLEX-NK multifunctional engager antibody
and iNK cells. Cytovia may not actually achieve the plans,
intentions or expectations disclosed in these forward-looking
statements, and you should not place undue reliance on these
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
these forward-looking statements as a result of various factors,
including whether the outcome of preclinical studies will be
predictive of clinical trial results. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Cytovia expressly disclaims any obligation to
update any forward-looking statements contained herein, whether
because of any new information, future events, changed
circumstances or otherwise, except as otherwise required by
law.
No Offer or Solicitation
This communication is for
informational purposes only and is neither an offer to purchase,
nor a solicitation of an offer to sell, subscribe for or buy, any
securities or the solicitation of any vote in any jurisdiction
pursuant to the Business Combination or otherwise, nor shall there
be any sale, issuance or transfer or securities in any jurisdiction
in contravention of applicable law
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cytovia-therapeutics-to-present-in-vivo-multiple-myeloma-data-of-its-cd38-targeting-flex-nk-cell-engager-at-eha-2022-congress-301549879.html
SOURCE Cytovia Therapeutics